Back to Career Page

Chief Medical Officer

Location: United States

Job Overview:

Gameto is seeking a dynamic reproductive endocrinologist (REI) to serve as the Chief Medical Officer to lead US Clinical trial development and global clinical use of its in vitro maturation (IVM) product Fertilo. Gameto’s lead product, Fertilo, is aimed at improving IVF & egg freezing processes by using iPSC-derived ovarian support cells (OSCs) to mature immature eggs outside the body, making the process shorter, safer, and more accessible. Fertilo is currently being used clinically & commercially ex-US and is preparing for a Phase III Randomized Control Trial in the United States.

A successful candidate will play a pivotal role in steering our clinical operations, ensuring the highest clinical standards, working directly with the clinical trial and data management teams, as well as the scientific development teams to improve treatment outcomes and clinical implementation. This position demands a forward-thinking and adaptable professional who can thrive in a dynamic and rapidly evolving environment. You will lead our clinical initiatives for fertility physicians, drive innovation in reproductive medicine and clinical adoption, and serve a key role in our clinical trial and study operations. This candidate is a strong leader with an entrepreneurial mindset, excellent communication and presentation skills, and is dedicated to the advancement of novel approaches to IVF.



About Gameto:

Gameto is a private biotechnology company in women’s health. Gameto is led by physician-turned-entrepreneur Dina Radenkovic as a co-founder & CEO and a serial entrepreneur & leader in the fertility space, Martin Varsavsky, founder of Prelude Network, one of the largest proprietary fertility clinics chain in the US, as Chairman.

Gameto’s underlying science platform was developed with a sponsored research agreement with Harvard University/Wyss Institute. We are using the cell engineering platform to develop novel treatment solutions for infertility and other diseases of the female reproductive system. Last year we published that our cell engineering platform of the female ovary developed with Professor George Church’s lab at Harvard Medical School surpasses the previous gold standard animal models.

Gameto has raised $40 million in a Series A from funds such as Insight Partners, Future Ventures, Lux Capital, Bold Capital, Bob Nelsen & Anne Wojcicki. Gameto currently has about $22m cash on hand. Our team is mission-driven, kind, collaborative, and authentic. Read about Gameto in MIT Technology Review, The New Yorker, The Boston Globe, and Stat News. We are an equal opportunity employer and value diversity at our company; we do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

If interested in this position, please send the following to with the email subject “Chief Medical Officer (your full name)”:

Apply Here